PYXS250117C3000
- 0.00
- 0.000.00%
Pyxis Oncology Newsroom
RBC Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Cuts Target Price to $8
H.C. Wainwright Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Cuts Target Price to $5
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating
Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move
Express News | Pyxis Oncology, Inc. : H.c. Wainwright Cuts Target Price to $5 From $7
Pyxis Oncology Analyst Ratings
RBC Cuts Price Target on Pyxis Oncology to $8 From $10, Keeps Outperform, Speculative Risk
Pyxis Oncology to Focus Resources on Lead Clinical Program PYX-201
Express News | Refile- Pyxis Oncology- Company to Focus on Advancing Lead Asset, Pyx-201 (Adds Dropped Words)
Express News | Pyxis Oncology Shares up 5.2% at $1.62 After the Bell Following Announcement of Portfolio Prioritization
Express News | Pyxis Oncology Inc - Current Cash Runway Expected to Fund Development Into 2H 2026
Express News | Pyxis Oncology Inc - - Company
Express News | Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on Its Lead Clinical Program, Pyx-201
CFO & COO of Pyxis Oncology Pamela Connealy Buys 13% More Shares
A Quick Look at Today's Ratings for Pyxis Oncology(PYXS.US), With a Forecast Between $7 to $10
Institutional Investors in Pyxis Oncology, Inc. (NASDAQ:PYXS) See US$130m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Sector Update: Health Care Stocks Advance Late Afternoon
Sector Update: Health Care
Pyxis Oncology Shares Slump After William Blair Downgrade